• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 14, 2018

View Archived Issues

In the clinic

Protalix Biotherapeutics Inc., of Carmiel, Israel, reported results from a phase II trial testing OPRX-106, recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain, in 24 patients with active mild to moderate ulcerative colitis.  Read More

Regulatory front

Stakeholders must work together to maximize the value and affordability of cancer treatments in the U.S. and support the investments in science and research that will drive future innovations, the President's Cancer Panel concluded in a new report that calls for urgent action to better align the prices of cancer drugs with their value.  Read More

Other news to note

Neuralstem Inc., of Germantown, Md., said a publication in Nature Medicine showed that NSI-566, its lead cell therapy candidate, provided meaningful improvement in forelimb function in a nonhuman primate model of acute spinal cord injury.  Read More

Financings

Escalier Biosciences BV, of Nijmegen, the Netherlands, has closed a $19 million series B financing led by Forbion with existing investors New Science Ventures and Biogeneration Ventures.  Read More

Israel's Mybiotics scores second option agreement for microbiome therapeutics

HONG KONG –With a new deal with Ferring Holdings Ltd. to option its innovative microbiome-focused technology, Israel's Mybiotics Pharma Ltd. is looking to expand its market and develop new products. Its second option agreement with Ferring is based on validation of Mybiotics' microbiome-based therapeutic technology focused on women's health. Read More

Targeting single signaling node affects multiple ALK resistance mutations

In cell lines directly generated from patients with anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers that were resistant to second-generation ALK inhibitors, multiple different bypass resistance mutations ultimately converged on the same signaling mode to increase cell growth. Read More

Finding incentives to develop antibiotics in an antibacterial- and funding-resistant world

AMSTERDAM – A growing epidemic of antimicrobial-resistance (AMR) has cast a heavy load on the laps of antibiotic drug developers. They face challenges in identifying new targets and the particular organism causing the infection, in finding patients to treat at the right time, and in understanding variability in response. If that isn't enough, the money is scarce, costing the same in development as many other drugs, but lacking the blockbuster potential. Read More

Biondvax puts pegs in place for final push in universal flu vaccine effort

With regulatory support from the EMA and financial backing from the European Investment Bank (EIB), Biondvax Pharmaceuticals Ltd. moved a step closer to initiating the pivotal phase III trial of its universal flu vaccine candidate, Multimeric-001 (M-001), by putting a master service agreement in place with a contract research organization (CRO) for the trial, expected to begin in the third quarter prior to the 2018-19 Northern Hemisphere flu season. Read More

Academic scientist injects dose of reality into microbiome debate

AMSTERDAM – Scientist Jeroen Raes was a latecomer to an early morning panel on "nutrition, lifestyle and medicines in the patient's journey," which kicked off day two of BIO-Europe Spring. But his arrival injected a hefty dose of realism – and expertise – into a discussion of an area that has attracted large quantities of hype and cash but has yet to deliver any clinically useful products, never mind compelling clinical data. Read More

Puretech adds $100M to boost in-house pipeline, invest in affiliate firms

LONDON - Quoted technology commercialization specialist Puretech Health plc raised £72 million (US$100 million) in a placing, providing funds to advance its wholly owned pipeline of treatments targeting the lymphatic system and to co-invest in upcoming funding rounds for its affiliate companies. Read More

Fatality draws FDA hold for Advaxis carcinoma study

The death of a woman in a study combining Advaxis Inc.'s lead immunotherapy candidate, axalimogene filolisbac (axal), and Astrazeneca plc's Imfinzi (durvalumab) to treat two types of carcinoma has triggered an FDA clinical hold, halting further dosing and enrollment in the study. Although the final cause of death is still under investigation, a spokesperson for Advaxis told BioWorld that initial reports point to respiratory failure. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe